How have IMRX and STRO total returns compared?

Over the past 5 years, IMRX delivered -32.77% and STRO delivered -39.51% annualized total return. Past performance doesn't predict future results.

Immuneering Corporation (IMRX) vs Sutro Biopharma, Inc. (STRO)

A side-by-side comparison of Immuneering Corporation and Sutro Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

IMRX

Immuneering Corporation

$140M

$3.86HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

STRO

Sutro Biopharma, Inc.

$140M

$14.46HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT

Total return — IMRX vs STRO

growth of $100 · dividends reinvested · last 5y

IMRX -77.0% (-25.5%/yr)STRO -91.1% (-38.4%/yr)IMRX compounded faster over this window

IMRX STRO

IMRX vs STRO: by the numbers

•IMRX is the larger company ($140M vs $140M market cap).
•Both run net losses; IMRX's is the smaller (0.00% vs -395.25% net margin).

Metrics side by side

Valuation

Metric	IMRX	STRO
P/S ratio	N/A	3.06
P/B ratio	0.73	N/A

Profitability

Metric	IMRX	STRO
Gross margin	0.00%	97.20%
Operating margin	0.00%	-102.41%
Net margin	0.00%	-395.25%
ROE	-30.03%	N/A
ROIC	-32.73%	-100.04%

Growth (annualized)

Metric	IMRX	STRO
Revenue CAGR (5Y)	N/A	19.13%
Total return CAGR (5Y)	-32.77%	-39.51%

Frequently asked

How have IMRX and STRO total returns compared?: Over the past 5 years, IMRX delivered -32.77% and STRO delivered -39.51% annualized total return. Past performance doesn't predict future results.

Go deeper

Full IMRX analysis Full STRO analysis Interactive comparison tool

Dig into the metrics

Immuneering ROE Sutro Biopharma ROE Immuneering operating margin Sutro Biopharma operating margin Immuneering revenue growth Sutro Biopharma revenue growth Immuneering free cash flow Sutro Biopharma free cash flow

Immuneering & Sutro Biopharma appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.